View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEvolva Holding 将来の成長Future 基準チェック /06現在、 Evolva Holdingの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長8.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024お知らせ • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.お知らせ • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.お知らせ • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.お知らせ • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).分析記事 • Nov 21We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Nov 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).お知らせ • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.お知らせ • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.分析記事 • Jun 09Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 05Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A CatchThere wouldn't be many who think Evolva Holding SA's ( VTX:EVE ) price-to-sales (or "P/S") ratio of 4.4x is worth a...Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Chemicals industry in Switzerland.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67%, compared to a 12% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year and the company’s share price has also fallen by 20% per year.お知らせ • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.お知らせ • Aug 25+ 1 more updateEvolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023お知らせ • May 25Evolva Holding SA announced that it has received CHF 6.3226 million in fundingEvolva Holding SA announced a private placement of 62,600,000 common shares at a price of CHF 0.101 per share for gross proceeds of CHF 6,322,600 on May 24, 2022. The transaction included participation from long-term oriented institutional investors, selected members of the Board of Directors and management for CHF 1,000,000.お知らせ • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.分析記事 • Mar 22Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.Reported Earnings • Mar 12Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 140%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year.お知らせ • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.お知らせ • Dec 28Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 12 million on December 27, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2023. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.分析記事 • Dec 01Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.お知らせ • May 17Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 20 million on May 17, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2022. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.分析記事 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.Price Target Changed • Mar 03Price target raised to CHF0.32Up from CHF0.29, the current price target is an average from 2 analysts. The new target price is 43% above the current share price of CHF0.22. As of last close, the stock is down 2.6% over the past year.Analyst Estimate Surprise Post Earnings • Mar 03Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 28%. Earnings per share (EPS) exceeded analyst estimates by 38%. Over the next year, revenue is forecast to grow 59%, compared to a 7.6% growth forecast for the Chemicals industry in Switzerland.お知らせ • Mar 03Evolva Announces Management ChangesEvolva announced that André Pennartz, CFO of Evolva, is leaving the company for personal reasons with immediate effect. Oliver Walker will take on the role of CFO ad interim until a successor is appointed.Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.分析記事 • Feb 13Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the Evolva Holding SA ( VTX:EVE ) share...お知らせ • Jan 21Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing SugarEvolva launched L-arabinose (previously known as EVE-X157/Z4), a natural sugar blocker used in food and beverages and reducing sugar applied in food processing. As people around the world continue to strive to live a healthier lifestyle, they are committed to helping their customers create healthier, more sustainable solutions. Studies show that L-arabinose as sugar blocker can support healthy blood sugar levels and weight management. It also has potential application as a prebiotic. As reducing sugar, L-arabinose is also frequently applied in the production of savoury flavors such as chicken and beef. Made by fermentation, Evolva's L-arabinose is fully renewable and sustainable, it has a high-purity level (>99%) and no hydrochloric acid is used in the manufacturing process. L-Arabinose is FEMA GRAS approved for use in food and beverages. L-Arabinose taste profile is well-suited for use in products such as yogurt, chocolate, soft drinks, ice cream, cereal, power bars and confectionary. With a wide range of applications, L-arabinose has a current market value of CHF 250 million, which is expected to grow by at least 5% per annum. Evolva is having commercial discussions with major customers, which include first supply volumes for 2021.Is New 90 Day High Low • Jan 20New 90-day high: CHF0.24The company is up 11% from its price of CHF0.22 on 22 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.分析記事 • Dec 21We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • Nov 06Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021Evolva Holding SA announced that Effective January 1, 2021, Gerhard Lobmaier is appointed Evolva's Chief Operations Officer. In his role, he will lead the manufacturing and supply chain functions, supporting the optimization of the CMO network for Evolva, thus increasing security of supply and realizing cost savings. Prior to this appointment, he served in several global functions at Cognis and BASF.Is New 90 Day High Low • Oct 14New 90-day low: CHF0.23The company is down 17% from its price of CHF0.27 on 16 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Oct 14Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating OfficerProcessa Pharmaceuticals Inc. announced the appointment of Michael Floyd as the Company's Chief Operating Officer. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the phase 3 program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa.お知らせ • Aug 26Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021Evolva Holding SA announced that they will report fiscal year 2020 results at 5:01 AM, GMT Standard Time on Feb 25, 2021お知らせ • Jun 30Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with Nice & Green SA for a private placement of convertible securities for gross proceeds of up to CHF 12 million on June 29, 2020. The transaction will be completed in multiple tranches. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume on SIX during the six trading days preceding the conversion. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Evolva Holding は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測SWX:EVE - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20234-101-3-3N/A9/30/20238-98-8-6N/A6/30/202312-94-12-9N/A3/31/202314-69-17-14N/A12/31/202216-43-21-19N/A9/30/202214-44-27-24N/A6/30/202212-45-32-30N/A3/31/202211-43-33-30N/A12/31/202110-41-34-30N/A9/30/202110-41-32-27N/A6/30/202110-42-31-24N/A3/31/20219-36-30-24N/A12/31/20208-30-29-23N/A9/30/20208-27-24-19N/A6/30/20209-25-19-15N/A3/31/202010-23-19-13N/A12/31/201912-22-20-11N/A9/30/201912-23-24-15N/A6/30/201911-25-29-18N/A3/31/201910-27-33-21N/A12/31/20189-29-37-24N/A9/30/20188-31-39-29N/A6/30/20187-33-42-34N/A3/31/20187-36-39-35N/A12/31/20177-39-36-36N/A9/30/20178-38N/A-35N/A6/30/201710-37N/A-34N/A3/31/201710-37N/A-34N/A12/31/201610-36N/A-34N/A9/30/20169-35N/A-33N/A6/30/20169-34N/A-33N/A3/31/201611-33N/A-32N/A12/31/201513-32N/A-32N/A9/30/201514-30N/A-28N/A6/30/201514-28N/A-25N/A3/31/201512-25N/A-23N/A12/31/201411-21N/A-20N/A9/30/201410-19N/A-17N/A6/30/201410-18N/A-15N/A3/31/20149-17N/A-14N/A12/31/20139-16N/A-13N/A9/30/20138-15N/A-12N/A6/30/20137-14N/A-12N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EVEの予測収益成長が 貯蓄率 ( 0.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: EVEの収益がSwiss市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: EVEの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: EVEの収益がSwiss市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: EVEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EVEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/26 07:22終値2024/04/26 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Evolva Holding SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sebastian BrayBerenbergSara WelfordEdison Investment ResearchMartin VoegtliResearch Partners AG1 その他のアナリストを表示
お知らせ • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.
Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.
Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
お知らせ • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024
お知らせ • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.
お知らせ • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.
お知らせ • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.
お知らせ • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.
New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).
分析記事 • Nov 21We Think Evolva Holding (VTX:EVE) Has A Fair Chunk Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Nov 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).
New Risk • Sep 28New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).
New Risk • Sep 13New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m).
お知らせ • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.
お知らせ • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.
分析記事 • Jun 09Would Evolva Holding (VTX:EVE) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 05Evolva Holding SA (VTX:EVE) Screens Well But There Might Be A CatchThere wouldn't be many who think Evolva Holding SA's ( VTX:EVE ) price-to-sales (or "P/S") ratio of 4.4x is worth a...
Reported Earnings • Mar 10Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021)Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Chemicals industry in Switzerland.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 27First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021)First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67%, compared to a 12% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year and the company’s share price has also fallen by 20% per year.
お知らせ • Aug 26Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025.
お知らせ • Aug 25+ 1 more updateEvolva Holding SA to Report Fiscal Year 2022 Results on Mar 09, 2023Evolva Holding SA announced that they will report fiscal year 2022 results on Mar 09, 2023
お知らせ • May 25Evolva Holding SA announced that it has received CHF 6.3226 million in fundingEvolva Holding SA announced a private placement of 62,600,000 common shares at a price of CHF 0.101 per share for gross proceeds of CHF 6,322,600 on May 24, 2022. The transaction included participation from long-term oriented institutional investors, selected members of the Board of Directors and management for CHF 1,000,000.
お知らせ • May 08Evolva Holding SA Announces Management AppointmentsEvolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee.
Price Target Changed • Apr 27Price target decreased to CHF0.21Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year.
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
分析記事 • Mar 22Is Evolva Holding (VTX:EVE) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 15Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Price Target Changed • Mar 14Price target decreased to CHF0.23Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year.
Reported Earnings • Mar 12Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 140%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year.
お知らせ • Feb 08Evolva Holding SA Announces Executive ChangesEvolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months.
Breakeven Date Change • Jan 21Forecast to breakeven in 2023The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
お知らせ • Dec 28Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 12 million on December 27, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2023. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.
分析記事 • Dec 01Is Evolva Holding (VTX:EVE) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Aug 29First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020)The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
お知らせ • May 17Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 20 million on May 17, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2022. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion.
分析記事 • Apr 01Shareholders Will Probably Hold Off On Increasing Evolva Holding SA's (VTX:EVE) CEO Compensation For The Time BeingThe underwhelming share price performance of Evolva Holding SA ( VTX:EVE ) in the past three years would have...
Executive Departure • Mar 10Chief Financial Officer has left the companyOn the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months.
Price Target Changed • Mar 03Price target raised to CHF0.32Up from CHF0.29, the current price target is an average from 2 analysts. The new target price is 43% above the current share price of CHF0.22. As of last close, the stock is down 2.6% over the past year.
Analyst Estimate Surprise Post Earnings • Mar 03Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 28%. Earnings per share (EPS) exceeded analyst estimates by 38%. Over the next year, revenue is forecast to grow 59%, compared to a 7.6% growth forecast for the Chemicals industry in Switzerland.
お知らせ • Mar 03Evolva Announces Management ChangesEvolva announced that André Pennartz, CFO of Evolva, is leaving the company for personal reasons with immediate effect. Oliver Walker will take on the role of CFO ad interim until a successor is appointed.
Reported Earnings • Mar 02Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019)Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
分析記事 • Feb 13Evolva Holding's (VTX:EVE) Shareholders Are Down 70% On Their SharesWhile it may not be enough for some shareholders, we think it is good to see the Evolva Holding SA ( VTX:EVE ) share...
お知らせ • Jan 21Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing SugarEvolva launched L-arabinose (previously known as EVE-X157/Z4), a natural sugar blocker used in food and beverages and reducing sugar applied in food processing. As people around the world continue to strive to live a healthier lifestyle, they are committed to helping their customers create healthier, more sustainable solutions. Studies show that L-arabinose as sugar blocker can support healthy blood sugar levels and weight management. It also has potential application as a prebiotic. As reducing sugar, L-arabinose is also frequently applied in the production of savoury flavors such as chicken and beef. Made by fermentation, Evolva's L-arabinose is fully renewable and sustainable, it has a high-purity level (>99%) and no hydrochloric acid is used in the manufacturing process. L-Arabinose is FEMA GRAS approved for use in food and beverages. L-Arabinose taste profile is well-suited for use in products such as yogurt, chocolate, soft drinks, ice cream, cereal, power bars and confectionary. With a wide range of applications, L-arabinose has a current market value of CHF 250 million, which is expected to grow by at least 5% per annum. Evolva is having commercial discussions with major customers, which include first supply volumes for 2021.
Is New 90 Day High Low • Jan 20New 90-day high: CHF0.24The company is up 11% from its price of CHF0.22 on 22 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
分析記事 • Dec 21We're Keeping An Eye On Evolva Holding's (VTX:EVE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • Nov 06Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021Evolva Holding SA announced that Effective January 1, 2021, Gerhard Lobmaier is appointed Evolva's Chief Operations Officer. In his role, he will lead the manufacturing and supply chain functions, supporting the optimization of the CMO network for Evolva, thus increasing security of supply and realizing cost savings. Prior to this appointment, he served in several global functions at Cognis and BASF.
Is New 90 Day High Low • Oct 14New 90-day low: CHF0.23The company is down 17% from its price of CHF0.27 on 16 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Oct 14Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating OfficerProcessa Pharmaceuticals Inc. announced the appointment of Michael Floyd as the Company's Chief Operating Officer. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the phase 3 program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa.
お知らせ • Aug 26Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021Evolva Holding SA announced that they will report fiscal year 2020 results at 5:01 AM, GMT Standard Time on Feb 25, 2021
お知らせ • Jun 30Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SAEvolva Holding SA (SWX:EVE) announced that it has entered into an agreement with Nice & Green SA for a private placement of convertible securities for gross proceeds of up to CHF 12 million on June 29, 2020. The transaction will be completed in multiple tranches. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume on SIX during the six trading days preceding the conversion.